A Phase III Study of Durvalumab (MEDI4736) with or Without Tremelimumab for Previously Treated Patients with Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

Clinical Lung Cancer

Volumn 17, Issue 3, 2016, Pages 232-236.e1

  Planchard, David ^a   Yokoi, Takashi ^b   McCleod, Michael J ^c   Fischer, Jürgen R ^d   Kim, Young Chul ^e   Ballas, Marc ^f   Shi, Kelvin ^f   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c Florida Cancer Specialists   (United States)

^d Department of Internal Medicine II   (Germany)

^e Chonnam National University Medical School   (South Korea)

^f ASTRAZENECA   (United Kingdom)

Author keywords

ALK; Anti CTLA 4; Anti PD L1; EGFR; Tumor membrane staining

Indexed keywords

DURVALUMAB; ERLOTINIB; GEMCITABINE; NAVELBINE; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; MONOTHERAPY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; IMMUNOLOGY; LUNG NEOPLASMS; METASTASIS; METHODOLOGY; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; DRUG THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PLATINUM COMPOUNDS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84971637115     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.03.003     Document Type: Article

References (17)

1. K.N. Syrigos, M.W. Saif, E.M. Karapanagiotou, G. Oikonomopoulos, and F. De Marinis The need for third-line treatment in non-small cell lung cancer: an overview of new options Anticancer Res 31 2011 649 659
2. L. Carbognin, S. Pilotto, M. Milella, and et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers PLoS One 10 2015 e0130142
3. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
4. P. Kvistborg, D. Philips, S. Kelderman, and et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response Sci Transl Med 6 2014 254ra128
5. H. Borghaei, L. Paz-Ares, L. Horn, and et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 2015 1627 1639
6. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Poster presented at the 51st American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 8032. Available at: http://meetinglibrary.asco.org/content/147607-156. Accessed: April 1, 2016.
7. E.B. Garon, N.A. Rizvi, R. Hui, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2015 2018 2028
8. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2015 123 135
9. ® [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme, October 2015. Available at: https://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf. Accessed: November 15, 2015.
10. N.A. Rizvi, J. Mazières, D. Planchard, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 2015 257 265
11. R. Stewart, M. Morrow, S.A. Hammond, and et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody Cancer Immunol Res 3 2015 1052 1062
12. A.I. Spira, K. Park, J. Mazières, and et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) J Clin Oncol 33 15 Suppl 2015 8010
13. A.A. Tarhini Tremelimumab: a review of development to date in solid tumors Immunotherapy 5 2013 215 229
14. S. Antonia, S.B. Goldberg, A. Balmanoukian, and et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study Lancet Oncol 17 2016 299 308
15. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
16. S.J. Antonia, S.N. Gettinger, L.Q. Chow, and et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results J Clin Oncol 32 15 Suppl 2014 8023 (Abstract)
17. Rizvi NA, Gettinger SN, Goldman JW, et al. Safety and efficacy of first-line nivolumab (NIVO; antiprogrammed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). Oral presentation at the 16th World Conference on Lung Cancer; September 6-9, 2015; Denver, CO. Abstract S176. Available at: http://www.jto.org/article/S1556-0864(16)30010-7/abstract. Accessed: April 1, 2016.